Elder EE, Kennedy CW, Gluch L, Carmalt HL, Janu NC, Joseph MG, et al. Patterns of breast cancer relapse. Eur J Surg Oncol. 2006;32:922–7.
Guth U, Moch H, Herberich L, Holzgreve W. Noninflammatory breast carcinoma with skin involvement. Cancer. 2004;100:470–8.
Guth U, Wight E, Schotzau A, Langer I, Dieterich H, Rochlitz C, et al. A new approach in breast cancer with non-inflammatory skin involvement. Acta Oncol. 2006;45:576–83.
Waldman RA, Finch J, Grant-Kels JM, Stevenson C, Whitaker-Worth D. Skin diseases of the breast and nipple: Benign and malignant tumors. J Am Acad Dermatol. 2019;80:1467–81.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.
Haffty BG, Hauser A, Choi DH, Parisot N, Rimm D, King B, et al. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer. 2004;100:252–63.
Andry G, Suciu S, Vico P, Faverly D, Andry-t’Hooft M, Verhest A, et al. Locoregional recurrences after 649 modified radical mastectomies: incidence and significance. Eur J Surg Oncol. 1989;15:476–85.
Zhou D, Li M, Xu F, Zheng Q, Lu Q, Hong R, et al. The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence. Ann Med. 2023;55:2232299.
Hsi RA, Antell A, Schultz DJ, Solin LJ. Radiation therapy for chest wall recurrence of breast cancer after mastectomy in a favorable subgroup of patients. Int J Radiat Oncol, Biol, Phys. 1998;42:495–9.
Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, et al. Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:480–6.
Sutherland CM, Mather FJ. Long-term survival and prognostic factors in patients with regional breast cancer (skin, muscle, and/or chest wall attachment). Cancer. 1985;55:1389–97.
Heath WR, Carbone FR. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol. 2013;14:978–85.
Carroll SL, Pasare C, Barton GM. Control of adaptive immunity by pattern recognition receptors. Immunity. 2024;57:632–48.
Wu X, Xu F. Dendritic cells during Staphylococcus aureus infection: subsets and roles. J Transl Med. 2014;12:358.
Ma M, Jiang W, Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024;57:752–71.
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24.
Heras-Murillo I, Adan-Barrientos I, Galan M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21:257–77.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5:66.
Zagorulya M, Spranger S. Once upon a prime: DCs shape cancer immunity. Trends Cancer. 2023;9:172–84.
Su S, Zhao J, Xing Y, Zhang X, Liu J, Ouyang Q, et al. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell. 2018;175:442–57.e23.
Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, et al. Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin. Nature. 2019;565:366–71.
Greaves E, Horne AW, Jerina H, Mikolajczak M, Hilferty L, Mitchell R, et al. EP2 receptor antagonism reduces peripheral and central hyperalgesia in a preclinical mouse model of endometriosis. Sci Rep. 2017;7:44169.
Gao J, Xiong T, Grabauskas G, Owyang C. Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell–prostaglandin E2. Gastroenterology. 2022;162:1962–74.e6.
Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257–70.
Kashem SW, Haniffa M, Kaplan DH. Antigen-presenting cells in the skin. Annu Rev Immunol. 2017;35:469–99.
van Vlerken-Ysla L, Tyurina YY, Kagan VE, Gabrilovich DI. Functional states of myeloid cells in cancer. Cancer Cell. 2023;41:490–504.
Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257–62.
Kramer K, Young SL, Walker GF. Data on the uptake of reducible antigen-adjuvant conjugates by dendritic cells. Data Brief. 2019;23:103759.
Lindner B, Burkard T, Schuler M. Phagocytosis assays with different pH-sensitive fluorescent particles and various readouts. Biotechniques. 2020;68:245–50.
Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, et al. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature. 2024;625:593–602.
Tvingsholm SA, Frej MS, Rafa VM, Hansen UK, Ormhøj M, Tyron A, et al. TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy. Journal for immunotherapy of cancer. 2023;11.
Lee PJ, Sui YH, Liu TT, Tsang NM, Huang CH, Lin TY, et al. Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPalpha signaling in fibroblasts. J Exp Clin Cancer Res CR. 2022;41:254.
O’Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol. 2015;172:5239–50.
Bayerl F, Meiser P, Donakonda S, Hirschberger A, Lacher SB, Pedde AM, et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity. 2023;56:1341–58.e11.
Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172:1022–37.e14.
Guerrero-Juarez CF, Lee GH, Liu Y, Wang S, Karikomi M, Sha Y, et al. Single-cell analysis of human basal cell carcinoma reveals novel regulators of tumor growth and the tumor microenvironment. Sci Adv. 2022;8:eabm7981.
Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol. 2014;14:289–301.
Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, et al. Immune characterization of breast cancer metastases: prognostic implications. Breast Cancer Res BCR. 2018;20:62.
Lam B, Kung YJ, Lin J, Tseng S-H, Tu H-F, Huang C, et al. In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy. J Clin Investig. 2024;134:e171621.
Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74–95.
Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10:5408.
Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Investig. 2013;123:3135–45.
Pelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 2021;11:2602–19.